Humanigen Inc. (HGEN)

NASDAQ: HGEN · Delayed Price · USD
2.54
-0.07 (-2.68%)
At close: Jan 21, 2022 4:00 PM
2.55
0.01 (0.39%)
After-hours:Jan 21, 2022 5:17 PM EST
Market Cap162.10M
Revenue (ttm)2.87M
Net Income (ttm)-235.40M
Shares Out63.82M
EPS (ttm)-4.23
PE Ration/a
Forward PE9.39
Dividendn/a
Ex-Dividend Daten/a
Volume1,731,629
Open2.62
Previous Close2.61
Day's Range2.50 - 2.72
52-Week Range2.50 - 29.20
Beta-1.93
AnalystsBuy
Price Target21.13 (+731.9%)
Earnings Daten/a

About HGEN

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies t...

IndustryBiotechnology
IPO DateJan 31, 2013
CEOCameron Durrant
Employees10
Stock ExchangeNASDAQ
Ticker SymbolHGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Humanigen stock is "Buy." The 12-month stock price forecast is 21.13, which is an increase of 731.89% from the latest price.

Price Target
$21.13
(731.89% upside)
Analyst Consensus: Buy

News

Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Econ...

BURLINGAME, Calif.--(BUSINESS WIRE)---- $HGEN--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

3 days ago - Business Wire

KaloBios Pharmaceuticals Inc. (HGEN) Upgraded to Buy: Here's What You Should Know

KaloBios Pharmaceuticals Inc. (HGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

4 days ago - Zacks Investment Research

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine ...

1 week ago - Business Wire

Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 ha...

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

2 weeks ago - Business Wire

Humanigen to Present at Investor Conferences January 7 and 13, 2022

BURLINGAME, Calif.--(BUSINESS WIRE)---- $HGEN--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

2 weeks ago - Business Wire

Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine ...

2 weeks ago - Business Wire

Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

1 month ago - Business Wire

After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News

Humanigen Inc (NASDAQ: HGEN) announced that The Lancet Respiratory Medicine published results from its LIVE-AIR Phase 3 trial of lenzilumab in hospitalized COVID-19 patients. The Lancet paper concludes,...

1 month ago - Benzinga

Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Cor...

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

1 month ago - Business Wire

The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 L...

BURLINGAME, Calif.--(BUSINESS WIRE)--The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

1 month ago - Business Wire

Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

1 month ago - Business Wire

Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

2 months ago - Business Wire

Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Up...

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update

2 months ago - Business Wire

Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease

2 months ago - Business Wire

Humanigen Announces Release of Abstracts at ASH

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Release of Abstracts at ASH

2 months ago - Business Wire

Humanigen Announces Participation and Presentation at Multiple Conferences in November

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

2 months ago - Business Wire

First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemi...

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced the first patient was dosed with lenzilumab in the Precision Approach to Chronic Myelomonocytic Leukemi...

2 months ago - Business Wire

European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19

BURLINGAME, Calif.--(BUSINESS WIRE)--European Commission selects Humanigen's lenzilumab as one of the 10 most promising treatments for COVID-19

2 months ago - Business Wire

Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 s...

BURLINGAME, Calif.--(BUSINESS WIRE)--An abstract showing ifabotuzumab tumor targeting at all known sites in glioblastoma patients with no normal tissue uptake will be presented at EANM‘21

2 months ago - Business Wire

Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

3 months ago - Business Wire

Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Bioma...

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with i...

3 months ago - Business Wire

Humanigen's Budget Impact Model Demonstrates Lenzilumab's Potential Positive Economic Value in Hospitalized COVID-19 ...

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

3 months ago - Business Wire

Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

3 months ago - Business Wire

Humanigen Announces Participation and Presentation at Multiple Conferences in October

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Participation and Presentation at Multiple Conferences in October

3 months ago - Business Wire

Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK's MHRA

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with i...

3 months ago - Business Wire